Stablepharma achieved a scientific breakthrough with a fridge-free Tetanus diphtheria (Td) vaccine

QUBE 28_2_22-09 OT.JPG

Stablepharma has achieved an important milestone with the Td-StablevaX-M™, having successfully demonstrated stability of the reformulated Td vaccine for up to 10 months at +45ºC in collaboration with our strategic partner BB–NCIPD Ltd (Bul Bio).

Td-StablevaX-M™ is a pre-filled disposable syringe containing dry stabilised tetanus diptheria vaccine for administration by injection following rehydration. Results demonstrate long-term stability at high temperatures, thereby solving a constant problem in vaccine distribution and the cold-chain.

Td-StablevaX-M™ is a reformulation of BB–NCIPD Ltd., Tetadif vaccine which is one of the five WHO pre-qualified Td vaccines that is distributed across many countries. Currently, Tetadif is in liquid form and indicated to be kept between +2ºC and +8ºC to avoid freezing.

Arcadio G. de Castro PhD, Chief Scientific Officer, Stablepharma, explained “We designed an accelerated stability study with our European partner BB–NCIPD Ltd, to evaluate stability after 10 months at +45ºC of Td vaccine, which was reformulated as StablevaX-M. We have evaluated adjuvant and toxoid integrity as well as in vivo potency. Potency tests were carried out under a fully qualified quality system following Pharmacopeia guidelines, and involved evaluation of the protection confered to animals by the vaccine against a lethal dose of the tetanus and diptheria toxins. The potency tests are the same as those used for batch release of commercial liquid vaccine, which under the same conditions, were found to completely lose effectiveness."

We are very happy with the observed results, as they exceed the current European Medicines Agency (EMA) requirement set for a “fridge-free” pharmaceutical product, which is to demonstrate stability at +40°C for 6 months.

Vaccine structural integrity was demonstrated by Enzyme Linked Immunoassay (ELISA) tests developed in collaboration with UK’s NIBSC showing that after 10 months at +45°C, tetanus and diphtheria toxoids in the control liquid vaccine were fully degraded while they remained unchanged in Td-StablevaX-M™.


When asked to summarise the results of the animal potency challenge trials, Özgür Tuncer said, “We are extremely pleased with the in vivo and in vitro results we have achieved with our partner BB-NPICD Ltd. These results clearly demonstrated that a commercial fridge-free Td vaccine is now within our reach. We are moving forward with the development of our first fridge-free vaccine StablevaX™-Td, in collaboration with our partners”.

“By eliminating the need for the cold-chain, fridge-free vaccines could result in health economic savings of up to $100 per patient in low income countries – this in itself is a huge incentive for us to progress our technology with our partners”, added Özgür.


More news and updates

BIA celebrates RQ BIO licencing agreement with AstraZeneca for monoclonal antibodies targeted at COVID-19

Today RQ BIO has announced a licencing agreement with AstraZeneca for its portfolio of early-stage monoclonal antibodies targeted against SARS-CoV-2, with the company also emerging from stealth mode on completion of the agreement. RQ Bio is a UK-based biotechnology company focused on developing treatments and preventative therapies based on potent broad-spectrum mAbs to address areas of unmet need in vulnerable patient populations.

CEO Update | 16 May 2022

Last week we gave our response to the Department of Work and Pensions consultation on facilitating investments in illiquid assets. We called on the UK Government to improve transparency in the pensions industry so that pension savers have access to diversified investment strategies benefiting from the wealth-creating opportunities of the UK’s innovative, venture capital-backed industries, including biotech and life sciences, while supporting issues the public care about, like better healthcare and a cleaner environment.

Give pension savers the opportunity to invest in the development of new medicines and a greener economy

The BioIndustry Association (BIA) has called on the UK Government to improve transparency in the pensions industry so that savers can make informed decisions on what their money is invested in.

CEO Update | 9 May 2022

Congratulations to Omass Therapeutics for raising $100 million in the Series B financing round, as well as two BIA member companies - Scotland-based EnteroBiotix and Solvemed group, who were featured in Forbes ‘30 under 30 Europe’ Science and Healthcare Edition for 2022. We are also glad to see engineering biology receive £20.6 million in investment from UK Research and Innovation (UKRI). Read more on IP TRIPS Waiver, update on Northern Ireland and BBSRC Business and Academia Prosperity Partnership.


More within